$OM
Outset Medical, Inc.

2024 Q4 Form 10-Q Financial Statement

#000095017024122518 Filed on November 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $28.67M
YoY Change -5.59%
Cost Of Revenue $18.85M
YoY Change -18.78%
Gross Profit $9.820M
YoY Change 37.21%
Gross Profit Margin 34.26%
Selling, General & Admin $25.52M
YoY Change -30.15%
% of Gross Profit 259.88%
Research & Development $8.139M
YoY Change -49.37%
% of Gross Profit 82.88%
Depreciation & Amortization $1.391M
YoY Change -4.73%
% of Gross Profit 14.16%
Operating Expenses $33.66M
YoY Change -36.02%
Operating Profit -$23.84M
YoY Change -47.55%
Interest Expense $6.068M
YoY Change 88.86%
% of Operating Profit
Other Income/Expense, Net $2.149M
YoY Change -16.48%
Pretax Income -$27.76M
YoY Change -39.78%
Income Tax $182.0K
% Of Pretax Income
Net Earnings -$27.94M
YoY Change -39.5%
Net Earnings / Revenue -97.47%
Basic Earnings Per Share -$0.55
Diluted Earnings Per Share -$0.55
COMMON SHARES
Basic Shares Outstanding 52.54M 52.09M
Diluted Shares Outstanding 50.50K

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $35.95M
YoY Change -72.12%
Cash & Equivalents $33.29M
Short-Term Investments $2.659M
Other Short-Term Assets $3.945M
YoY Change -34.25%
Inventory $61.44M
Prepaid Expenses
Receivables $34.26M
Other Receivables $0.00
Total Short-Term Assets $275.3M
YoY Change -3.0%
LONG-TERM ASSETS
Property, Plant & Equipment $9.492M
YoY Change -31.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $484.0K
YoY Change -49.64%
Total Long-Term Assets $17.62M
YoY Change -25.91%
TOTAL ASSETS
Total Short-Term Assets $275.3M
Total Long-Term Assets $17.62M
Total Assets $292.9M
YoY Change -4.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.295M
YoY Change 49.13%
Accrued Expenses $22.57M
YoY Change -34.95%
Deferred Revenue $12.77M
YoY Change 17.9%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $42.43M
YoY Change -19.98%
LONG-TERM LIABILITIES
Long-Term Debt $197.2M
YoY Change 103.73%
Other Long-Term Liabilities $5.456M
YoY Change -4.28%
Total Long-Term Liabilities $197.2M
YoY Change 103.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $42.43M
Total Long-Term Liabilities $197.2M
Total Liabilities $245.1M
YoY Change 57.61%
SHAREHOLDERS EQUITY
Retained Earnings -$1.100B
YoY Change 19.16%
Common Stock $1.112B
YoY Change 3.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $47.82M
YoY Change
Total Liabilities & Shareholders Equity $292.9M
YoY Change -4.77%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$27.94M
YoY Change -39.5%
Depreciation, Depletion And Amortization $1.391M
YoY Change -4.73%
Cash From Operating Activities -$20.57M
YoY Change -39.51%
INVESTING ACTIVITIES
Capital Expenditures $395.0K
YoY Change -49.36%
Acquisitions
YoY Change
Other Investing Activities $16.27M
YoY Change -46.81%
Cash From Investing Activities $15.88M
YoY Change -46.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 121.0K
YoY Change -97.05%
NET CHANGE
Cash From Operating Activities -20.57M
Cash From Investing Activities 15.88M
Cash From Financing Activities 121.0K
Net Change In Cash -4.572M
YoY Change 4472.0%
FREE CASH FLOW
Cash From Operating Activities -$20.57M
Capital Expenditures $395.0K
Free Cash Flow -$20.96M
YoY Change -39.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Payments For Restructuring
PaymentsForRestructuring
4920000
CY2024Q3 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Restructuring Charges
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges
83000
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Central Index Key
EntityCentralIndexKey
0001484612
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39513
dei Entity Registrant Name
EntityRegistrantName
Outset Medical, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-0514392
dei Entity Address Address Line1
EntityAddressAddressLine1
3052 Orchard Dr.
dei Entity Address City Or Town
EntityAddressCityOrTown
San Jose
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95134
dei City Area Code
CityAreaCode
669
dei Local Phone Number
LocalPhoneNumber
231-8200
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
OM
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52542024
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33287000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
68509000
CY2024Q3 us-gaap Short Term Investments
ShortTermInvestments
142346000
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
134815000
CY2024Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
34259000
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32980000
CY2024Q3 us-gaap Inventory Net
InventoryNet
61436000
CY2023Q4 us-gaap Inventory Net
InventoryNet
49215000
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3945000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5700000
CY2024Q3 us-gaap Assets Current
AssetsCurrent
275273000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
291219000
CY2024Q3 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3329000
CY2023Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
3329000
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9492000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
13273000
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4312000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5375000
CY2024Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
484000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
605000
CY2024Q3 us-gaap Assets
Assets
292890000
CY2023Q4 us-gaap Assets
Assets
313801000
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
4295000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5827000
CY2024Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
14719000
CY2023Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
19005000
CY2024Q3 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6749000
CY2023Q4 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
13459000
CY2024Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
2156000
CY2023Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
3712000
CY2024Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
12766000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
11727000
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1745000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1593000
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
42430000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
55323000
CY2024Q3 om Accrued Interest Noncurrent
AccruedInterestNoncurrent
2222000
CY2023Q4 om Accrued Interest Noncurrent
AccruedInterestNoncurrent
896000
CY2024Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
77000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
101000
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3157000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4482000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
197182000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
130113000
CY2024Q3 us-gaap Liabilities
Liabilities
245068000
CY2023Q4 us-gaap Liabilities
Liabilities
190915000
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52538000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52538000
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
50317000
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
50317000
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
52000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
50000
CY2024Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1111503000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1084515000
CY2024Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
352000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
68000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1064085000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-961747000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
47822000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
122886000
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
292890000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
313801000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28666000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30362000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
84222000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
99869000
CY2024Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
18846000
CY2023Q3 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
23205000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
56405000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
78581000
CY2024Q3 us-gaap Gross Profit
GrossProfit
9820000
CY2023Q3 us-gaap Gross Profit
GrossProfit
7157000
us-gaap Gross Profit
GrossProfit
27817000
us-gaap Gross Profit
GrossProfit
21288000
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8139000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16076000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
30508000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
44775000
CY2024Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
15417000
CY2023Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
24720000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
54593000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
74038000
CY2024Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10103000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11815000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34231000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
34892000
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
33659000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
52611000
us-gaap Operating Expenses
OperatingExpenses
119332000
us-gaap Operating Expenses
OperatingExpenses
153705000
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-23839000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-45454000
us-gaap Operating Income Loss
OperatingIncomeLoss
-91515000
us-gaap Operating Income Loss
OperatingIncomeLoss
-132417000
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2149000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2573000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7718000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7889000
CY2024Q3 us-gaap Interest Expense
InterestExpense
6068000
CY2023Q3 us-gaap Interest Expense
InterestExpense
3213000
us-gaap Interest Expense
InterestExpense
18046000
us-gaap Interest Expense
InterestExpense
9258000
CY2024Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-27758000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-46094000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-101843000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-133786000
CY2024Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
182000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
86000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
495000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
411000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-27940000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-46180000
us-gaap Net Income Loss
NetIncomeLoss
-102338000
us-gaap Net Income Loss
NetIncomeLoss
-134197000
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.55
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.55
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.93
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.93
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.98
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.98
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.72
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-2.72
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
50501
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
50501
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49913
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49913
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
51685
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
51685
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
49364
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
49364
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-27940000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-46180000
us-gaap Net Income Loss
NetIncomeLoss
-102338000
us-gaap Net Income Loss
NetIncomeLoss
-134197000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
654000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
140000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
284000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
311000
CY2024Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-27286000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-46040000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-102054000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-133886000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
122886000
CY2024Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2080000
CY2024Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
295000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8203000
CY2024Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-326000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-39944000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
93200000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
77000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9820000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-44000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-34454000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
68599000
CY2024Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
121000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6388000
CY2024Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
654000
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-27940000
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
47822000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
245990000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
4594000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
684000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
8538000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
451000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-43971000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
216286000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1043000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10105000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-280000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-44046000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
183108000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2916000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1186000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10893000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
140000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-46180000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
152063000
us-gaap Net Income Loss
NetIncomeLoss
-102338000
us-gaap Net Income Loss
NetIncomeLoss
-134197000
us-gaap Share Based Compensation
ShareBasedCompensation
24411000
us-gaap Share Based Compensation
ShareBasedCompensation
29536000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4322000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4364000
om Non Cash Lease Expense
NonCashLeaseExpense
1063000
om Non Cash Lease Expense
NonCashLeaseExpense
919000
om Non Cash Interest Expense
NonCashInterestExpense
1898000
om Non Cash Interest Expense
NonCashInterestExpense
1377000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
3890000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
5099000
om Provision For Inventories
ProvisionForInventories
644000
om Provision For Inventories
ProvisionForInventories
672000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-34000
us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-106000
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
1813000
us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
141000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3092000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
7564000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
12989000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-2607000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-1848000
us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
-440000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1507000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2251000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-3991000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
25000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-6327000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-4108000
om Increase Decrease In Accrued Warranty Liability
IncreaseDecreaseInAccruedWarrantyLiability
-1556000
om Increase Decrease In Accrued Warranty Liability
IncreaseDecreaseInAccruedWarrantyLiability
447000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1015000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
2114000
om Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1173000
om Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-962000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-99815000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-106931000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
869000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2387000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
150467000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
121262000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
147121000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
183250000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4215000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
59601000
om Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases
ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases
2284000
om Proceeds From Stock Options Exercised And Employee Stock Purchase Plan Purchases
ProceedsFromStockOptionsExercisedAndEmployeeStockPurchasePlanPurchases
10423000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
66524000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
68808000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
10423000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-35222000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-36907000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
71838000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76533000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36616000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
39626000
us-gaap Income Taxes Paid
IncomeTaxesPaid
472000
us-gaap Income Taxes Paid
IncomeTaxesPaid
403000
us-gaap Interest Paid Net
InterestPaidNet
15537000
us-gaap Interest Paid Net
InterestPaidNet
1836000
om Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
1173000
om Cash Paid For Amounts Included In Measurement Of Operating Lease Liabilities
CashPaidForAmountsIncludedInMeasurementOfOperatingLeaseLiabilities
962000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
8000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
207000
om Transfer Of Inventories To Property And Equipment
TransferOfInventoriesToPropertyAndEquipment
148000
om Transfer Of Inventories To Property And Equipment
TransferOfInventoriesToPropertyAndEquipment
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
528000
us-gaap Net Income Loss
NetIncomeLoss
-102300000
us-gaap Net Income Loss
NetIncomeLoss
-134200000
us-gaap Payments For Operating Activities
PaymentsForOperatingActivities
99800000
us-gaap Payments For Operating Activities
PaymentsForOperatingActivities
106900000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1100000000
CY2024Q3 om Cash Cash Equivalents Restricted Cash And Short Term Investments
CashCashEquivalentsRestrictedCashAndShortTermInvestments
179000000
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
28666000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
30362000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
84222000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
99869000
CY2024Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
12900000
CY2024Q3 om Revenue Performance Obligation1
RevenuePerformanceObligation1
12800000
CY2024Q3 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P12M
CY2024Q3 om Revenue Performance Obligation1
RevenuePerformanceObligation1
100000
CY2024Q3 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2000000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
10900000
om Debt Securities Available For Sale Remaining Contractual Maturities Period
DebtSecuritiesAvailableForSaleRemainingContractualMaturitiesPeriod
one month to thirteen months
CY2024Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
2659000
CY2024Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
64877000
CY2023Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
74000
CY2024Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
0
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
3300000
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
3300000
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
33287000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36297000
CY2024Q3 us-gaap Restricted Cash
RestrictedCash
3329000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
3329000
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36616000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
39626000
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
203000
us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
1821000
us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
7000
CY2024Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
2017000
CY2024Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
25138000
CY2023Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
18706000
CY2024Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
13911000
CY2023Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
8728000
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
22387000
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
21781000
CY2024Q3 us-gaap Inventory Net
InventoryNet
61436000
CY2023Q4 us-gaap Inventory Net
InventoryNet
49215000
CY2024Q3 om Accrued Inventory Current
AccruedInventoryCurrent
1384000
CY2023Q4 om Accrued Inventory Current
AccruedInventoryCurrent
3395000
CY2024Q3 om Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
116000
CY2023Q4 om Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
1050000
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
716000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1153000
CY2024Q3 us-gaap Accrued Exchange Fee Rebate Current
AccruedExchangeFeeRebateCurrent
1738000
CY2023Q4 us-gaap Accrued Exchange Fee Rebate Current
AccruedExchangeFeeRebateCurrent
2100000
CY2024Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
2795000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
5761000
CY2024Q3 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
6749000
CY2023Q4 om Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
13459000
CY2024Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
200000000
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
133476000
CY2024Q3 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2818000
CY2023Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
3363000
CY2024Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
197182000
CY2023Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
130113000
om Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Percentage Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsPercentageVestedInPeriod
0.50
CY2024Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6388000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
10893000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24411000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
29536000
CY2024Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6137000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6137000
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4938000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4938000
CY2023Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Restructuring Charges
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges
854000
us-gaap Restructuring Charges
RestructuringCharges
4149000

Files In Submission

Name View Source Status
0000950170-24-122518-index-headers.html Edgar Link pending
0000950170-24-122518-index.html Edgar Link pending
0000950170-24-122518.txt Edgar Link pending
0000950170-24-122518-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
om-20240930.htm Edgar Link pending
om-20240930.xsd Edgar Link pending
om-ex31_1.htm Edgar Link pending
om-ex31_2.htm Edgar Link pending
om-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
om-20240930_htm.xml Edgar Link completed